BridgeBio Pharma, Inc.
NASDAQ:BBIOBiotechnology
+$0.75 today
- Market cap
- $15.20B
- Beta
- 0.97
- P/E (TTM)
- -18.1
- EPS (TTM)
- -$3.73
Volume 3.55M
Average 2.49M
BBIO Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
BridgeBio Pharma, Inc.NASDAQ: BBIO
Cash & Equivalents · Q2 FY2026 · quarter ended Jun 2026
Cash & equivalents falls 9.5% from a year ago
Cash & equivalents stood at $677.91M at the end of Q2 FY2026, down 9.5% from a year earlier and down 23.0% from the prior quarter. Over 3 fiscal years it compounded at +14.8% a year.
Context
- Cash & equivalents amounted to 55.7% of total assets at the end of Q2 FY2026, down 13.7 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -9.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 570.12M USD
- Year-over-year change
- -16.3%
- 4-year CAGR
- +9.7%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 570.12M | -16.3% |
| FY2024 | 2024-12-31 | 681.1M | +81.2% |
| FY2023 | 2023-12-31 | 375.94M | -0.2% |
| FY2022 | 2022-12-31 | 376.69M | -4.3% |
| FY2021 | 2021-12-31 | 393.77M | — |
Cash & Equivalents vs competitors
How BBIO compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -9.5% is the 9th highest of 11, against a peer median of +32.7%.
- Cash & equivalents amounts to 55.7% of total assets for BBIO, versus a peer median of 24.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $736.01B USD | +58775.5% | +21.9% | 6.4% | |
| Jun 2026 | $1.71B USD | +53.4% | +24.1% | 30.7% | |
| Jun 2026 | $1.05B USD | +3.2% | +52.1% | 32.3% | |
| Sep 2026 | €964.36M EUR | +78.9% | +11.5% | 39.7% | |
| Jun 2026 | $677.91M USD | -9.5% | +14.8% | 55.7% | |
| Sep 2026 | $366.27M USD | +27.7% | +46.3% | 82.1% | |
| Sep 2026 | $296.3M USD | -12.4% | +10.4% | 10.2% | |
| Jun 2026 | $201.53M USD | +42.7% | -2.0% | 17.4% | |
| Mar 2026 | $198.77M USD | -32.5% | +23.7% | 47.4% | |
| Mar 2026 | $175M USD | +37.7% | +48.3% | 13.5% | |
| Sep 2026 | $123.54M USD | +11.4% | +14.7% | 14.6% | |
| Peer median (excluding BBIO) | — | +32.7% | +22.8% | 24.1% | |
Competitors are the stored peer set for BBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 393.77M | 376.69M | 375.94M | 681.1M | 570.12M |
| Short-term Investments | 442.89M | 95.23M | 58.95M | 0 | 17.36M |
| Net Receivables | 19.75M | 17.08M | 1.75M | 4.72M | 139.44M |
| Inventory | 0 | 0 | 0 | 0 | 26.75M |
| Other Current Assets | 177K | 37.93M | 27.65M | 3.83M | 0 |
| Total Current Assets | 888.86M | 548.85M | 477.59M | 720.69M | 753.68M |
| Property, Plant & Equipment (Net) | 45.97M | 25.25M | 19.84M | 12.78M | 13.52M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 44.93M | 28.71M | 26.32M | 23.93M | 28.08M |
| Long-term Investments | 2.42M | 2.87M | 3.74M | 143.75M | 81.44M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 30.61M | 17.36M | 18.88M | 18.2M | (81.44M) |
| Total Non-current Assets | 123.93M | 74.18M | 68.79M | 198.65M | 41.59M |
| Total Assets | 1.01B | 623.04M | 546.38M | 919.34M | 936.03M |
| Account Payables | 11.88M | 11.56M | 10.66M | 9.62M | 36.23M |
| Short-term Debt | 0 | 0 | 0 | 0 | 17.41M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 8.16M | 6.1M | 0 | 20.27M |
| Other Current Liabilities | 37.04M | 31.26M | 65.6M | 16.2M | 214.06M |
| Total Current Liabilities | 135.07M | 121.43M | 143.84M | 154.4M | 287.97M |
| Long-term Debt | 1.7B | 1.71B | 1.73B | 1.72B | 2.71B |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 13.08M |
| Other Non-current Liabilities | 22.07M | 26.64M | 9.36M | 496.47M | 244K |
| Total Non-current Liabilities | 1.74B | 1.75B | 1.75B | 2.22B | 2.72B |
| Total Liabilities | 1.88B | 1.87B | 1.89B | 2.38B | 3.01B |
| Common Stock | 154K | 157K | 181K | 196K | 202K |
| Retained Earnings | (1.44B) | (1.92B) | (2.56B) | (3.1B) | (3.82B) |
| Accumulated OCI | (132K) | (328K) | 31K | 8K | 12K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 4.84M | 9.69M | 11.72M | 10.29M | (570K) |
| Total Equity | (865.58M) | (1.24B) | (1.34B) | (1.46B) | (2.08B) |
| Total Debt | 1.73B | 1.72B | 1.74B | 1.73B | 2.73B |
| Net Debt | 1.33B | 1.35B | 1.36B | 1.05B | 2.16B |
BridgeBio Pharma, Inc.
NASDAQ:BBIO
Intrinsic Alpha fair value
Locked
Current Price
$78.01
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.